Bio
Dr. Rawlins’ training and experience has been centered on the organic synthesis of molecules with potential medicinal value. His PhD thesis included a project to develop the total synthesis of paclitaxel (Taxol). After this training, he spent twenty years in the pharmaceutical industry as a medicinal chemist involved in drug discovery. His research groups focused on several different therapeutic areas including oncology, metabolic disease, and ophthalmology as well as cheminformatics. His work has led to several compounds that have entered into clinical trials, including an inhibitor of LIM domain kinase 2 (LIMK2) for glaucoma, sotagliflozin, a dual inhibitor of sodium-glucose cotransporter (SGLT) 1 and SGLT2, and LX2761. Since joining Roseman University of Health Sciences, Dr. Rawlins has been investigating potential antidepressants, essential oils, and drug delivery methods using 3D printing. He has developed informatics tools for tracking student information within the College of Pharmacy.
Education
Dr. Rawlins’ training and experience has been centered on the organic synthesis of molecules with potential medicinal value. His PhD thesis included a project to develop the total synthesis of paclitaxel (Taxol). After this training, he spent twenty years in the pharmaceutical industry as a medicinal chemist involved in drug discovery. His research groups focused on several different therapeutic areas including oncology, metabolic disease, and ophthalmology as well as cheminformatics. His work has led to several compounds that have entered into clinical trials, including an inhibitor of LIM domain kinase 2 (LIMK2) for glaucoma, sotagliflozin, a dual inhibitor of sodium-glucose cotransporter (SGLT) 1 and SGLT2, and LX2761. Since joining Roseman University of Health Sciences, Dr. Rawlins has been investigating potential antidepressants, essential oils, and drug delivery methods using 3D printing. He has developed informatics tools for tracking student information within the College of Pharmacy.
Research Interests
• The chemical synthesis of analogs of Ro-25-6981 (MI-4) as potential antidepressants.
• The composition and biological activity of essential oils.
• 3D printing as a method of drug delivery
Affiliation
• American Chemical Society, 1989-present
• American Association of Colleges of Pharmacy, 2016-present
• American Association of Pharmaceutical Scientists, 2016-present
Awards
• P1 Teacher of the Year, Roseman University of Health Sciences, 2018-2019
• Thomas A. Edison Patent Award, Research and Development Council of New Jersey, 2017
• Sigma Xi Outstanding Thesis from the College of Physical and Mathematical Sciences, Brigham Young University, 1990
• NSF Predoctoral Fellowship, Honorable Mention, 1988
• Trustee’s Scholarship, Brigham Young University, 1982-1987
Subjects
• Biochemistry of nucleic acids.
• Pharmacogenomics
• Medicinal Chemistry
• Pharmaceutical Calculations
• Medical Spanish
Research Publications
Patents:
• Harrison, BA; Kimball, SD; Mabon, R; Rawlins, DB; Sodium glucose co-transporter inhibitors and methods of their use; US Patent 20169365602, June 2016.
• Carson, KG; Goodwin, NC; Harrison, BA; Rawlins, DB; Strobel, E; Zambrowicz, B; SGLT1 inhibitors and methods of their use; U.S. Patent 61/728373, November 2012.
• Goodwin, NC; Rawlins, DB; 5-(1H-Pyrazol-5-yl)thiazole compounds for the treatment of eye diseases; WO Patent 2011091204, January 2011.
Publications:
• Riccio, KK; Rawlins, DB; Talbot, JN; Boyd, CJ; Demonstration of smartphones as viable tools for adolescent substance use surveillance: completion rate and response comparisons across electronic modes. Substance Use and Misuse, 2019, published online 12 Dec 2019, DOI: 10.1080/10826084.2019.1696822.
• Yellepeddi, VK; Zhudeva, MY; Movahedi, F; Vo, A; Phan, J; Kirsh, RD; Rawlins, DB; Talbot, JN; Biopharmaceutical characterization and oral efficacy of a new rapid acting antidepressant Ro 25-6981; J. Pharm. Sci., 2018, published online May 17, 2018.
• Talbot, JN; Rawlins, DB; Movahedi, F; Zhudeva, MY; Vo, A; Phan, J; Dorigatti, J; Velazquez, G; Kirsh RD; Yellepeddi, VK; The in vivo pharmacodynamic and biopharmaceutical characterization of a novel dual mechanism, rapid-acting antidepressant; The FASEB Journal, 2017, 31, Supplement 663.6.
• Powell, DR; Smith, MG; Doree, DD; Harris, AL; Greer, J; DaCosta, CM; Thompson, A; Liu, J; Jeter-Jones, S; Carson, K; Goodwin, NC; Harrison, BA; Rawlins, DB; Strobel, E; Gopinathan, S; Wilson, A; Mseeh, F; Sands, AT; Zambrowicz, B; Ding, Z-M; LX2761, an SGLT1 inhibitor restricted to the intestine, improves glycemic control in mice; J. Pharm. Exp. Ther., 2017, 362, 85-97.
• Goodwin, NC; Ding, Z-M; Harrison, BA; Strobel, E; Harris, A; Smith, M; Thompson, A; Xiong, W; Mseeh, F; Bruce, D; Diaz, D; Gopinathan, S; Li, L; O’Neill, E; Thiel, M; Wilson, A; Carson, K; Powell, D; Rawlins, DB; Discovery of LX2761, an SGLT1 inhibitor restricted to the intestinal lumen, for the treatment of diabetes; J. Med. Chem. 2017, 60, 710-721.
• Goodwin, NC.; Cianchetta, G; Burgoon, HA; Healy, J; Mabon, R; Strobel, ED; Allen, J; Wang, S; Hamman, BD; Rawlins, DB; Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation; Med. Chem. Lett. 2015, 6, 53-57.
• Harrison, BA; Almstead, ZY; Burgoon, H; Gardyan, M; Goodwin, NC; Healy, J; Liu, Y; Mabon, R; Marinelli, B; Samala, L; Zhang, Y; Stouch, T; Whitlock, NA; Hamman, BD; Gopinathan, S; McKnight, B; Crist, M; Wang, S; Patel, N; Wilson, AGE; Rice, DS; Rawlins, DB; The discovery and development of LX7101, a LIM-kinase 2 inhibitor for the treatment of glaucoma; Med. Chem. Lett. 2015, 6, 84–88.
• Powell, DR; Smith, MG; Doree, DD; Harris, AL; Xiong, WW, Mseeh, F; Wilson, A; Gopinathan, S; Diaz, D; Zambrowicz, B; Ding, ZM; Goodwin, NC, Harrison, BC; Strobel, E; Rawlins, DB; Carson, K; LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2; Pharmacol. Res. Perspect. 2015, 3, e00129.
• Zambrowicz, B; Freiman, J; Brown, PM; Frazier, KS; Turnage, A; Bronner, J; Ruff, D; Shadoan, M; Banks, P; Mseeh, F; Rawlins, DB; Goodwin, NC; Mabon, R; Harrison, BA; Wilson, A; Sands, A; Powell, DR; LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial; Clin. Pharmacol. Ther. 2012, 92, 158-169.